Inclusion Criteria:

- Must have relapsed or refractory Chronic Lymphocytic Leukemia (CLL), received no more
than 5 prior myelosuppressive/chemotherapy regimens and must be a candidate for
treatment with either Fludarabine/Cyclophosphamide/Rituximab (FCR) or
Bendamustine/Rituximab (BR);

- Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of
- Must have adequate bone marrow independent of growth factor support (with the
exception of subjects with bone marrow heavily infiltrated with underlying disease
[80% or more] who may use growth factor support to achieve Absolute Neutrophil Count
(ANC) eligibility criteria), per local laboratory reference range at Screening as
follows: ANC >/=1000/mcL, Platelets>/= 100,000/mm3 (entry platelet count must be
independent of transfusion within 14 days of Screening),Hemoglobin >/= 9.0 g/dL.

Exclusion Criteria:

- Subject has history or is clinically suspicious for cancer-related Central Nervous
System disease;

- Has history of severe allergic or anaphylactic reactions to human, humanized,
chimeric or murine monoclonal antibodies;

- Has undergone an allogeneic stem cell transplant; Exhibits evidence of other
uncontrolled condition(s) including, but not limited to: uncontrolled systemic
infection, diagnosis of fever and neutropenia within 1 week prior to study drug
administration;

- Has underlying, predisposing condition of bleeding or currently exhibits signs of
bleeding; Has a recent history of non-chemotherapy induced thrombocytopenic
associated bleeding;

- Currently receiving or requires anticoagulation therapy;

- Has active immune thrombocytopenic purpura (ITP) or a history of being refractory to
platelet transfusions (within 1 year prior to 1st dose of study drug);

- Has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.